Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 2;77(3):355–363. doi: 10.1136/annrheumdis-2017-211631

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Efficacy endpoints, by visit (modified intent-to-treat population). (A) SRI4 response; (B) SELENA-SLEDAI ≥4 point reduction; (C) SRI7 response and (D) time to first severe flare. *P<0.05 (logistic regression model for belimumab vs placebo with independent variables treatment group, country, baseline SELENA-SLEDAI score (≤9 vs ≥10) and baseline complement levels (low C3 and/or C4 vs no low C3 or C4)). C3/C4, complement 3/complement 4; SELENA-SLEDAI, Safety of Oestrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index; SFI, SLE Flare Index; SRI, SLE Responder Index.